PART I . Overview We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentia...
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001759138-26-000011 | EDGAR | 111K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047201 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034422 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008298 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0001564590-22-010726 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001564590-21-013329 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001564590-20-013929 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001193125-25-273280 | EDGAR | 79K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104573 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-071971 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126733 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093325 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060045 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061528 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040966 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020849 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024168 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016650 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001564590-22-019677 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-23 | 0001759138-26-000010 | EDGAR | 3K words |
| 2026-01-12 | 0001193125-26-009819 | EDGAR | — |
| 2025-11-10 | 0001193125-25-273272 | EDGAR | — |
| 2025-10-29 | 0001193125-25-254610 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250676 | EDGAR | — |
| 2025-10-09 | 0001193125-25-235533 | EDGAR | — |
| 2025-09-03 | 0001759138-25-000007 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104570 | EDGAR | — |
| 2025-06-12 | 0001193125-25-139517 | EDGAR | — |
| 2025-06-11 | 0001193125-25-138737 | EDGAR | — |
128 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001759138 |
| Ticker | CABA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.cabalettabio.com |
| Listed | 2019-10-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report